1357928-21-2

Basic information

• Product Name: benzyl ((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate
• Synonyms: benzyl ((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate
• CAS NO: 1357928-21-2
• Molecular Weight: 830.894
• Mol File: 1357928-21-2.mol

Chemical Properties

• CAS DataBase Reference: benzyl ((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl ((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate(1357928-21-2)
• EPA Substance Registry System: benzyl ((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate(1357928-21-2)

Safety Data

• Hazardous Substances Data: 1357928-21-2(Hazardous Substances Data)

Upstream product

• 68892-41-1 5'-O-dimethoxytrityl-N-isobutyryldeoxyguanosine 
• 1738-68-7 Gly-OBz 
• 1357928-20-1 (2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl) tetrahydrofuran-3-yl-1H-imidazole-1-carboxylate 

Downstream Products

• 1357928-19-8 C₃₃H₃₇N₆O₁₃P 
• 1357928-22-3 benzyl ((((2R,3S,5R)-2-(hydroxymethyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)carbonyl)glycinate 
• 1357928-23-4 C₂₈H₃₀N₈O₉ 
• 1357928-24-5 benzyl ((((2R,5R)-3-(((2-(benzyloxy)-2-oxoethyl)carbamoyl)oxy)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)carbonyl)glycinate 

Relevant articles and documents

Design, synthesis and structure-activity relationship of novel Relacin analogs as inhibitors of Rel proteins

Rel proteins in bacteria synthesize the signal molecules (p)ppGpp that trigger the Stringent Response, responsible for bacterial survival. Inhibiting the activity of such enzymes prevents the Stringent Response, resulting in the inactivation of long-term

COMPOUNDS FOR TREATING BACTERIAL INFECTIONS

The present invention generally relates to Rel proteins as a novel therapeutic target for treating bacterial threats. More specifically, the present invention relates to a novel class of compounds of formula (I) which inhibit RelA and/or Relseq and/or Rel